G007-LK Tankyrase 1/2 Inhibitor Workflows
2026-09-02
Build reproducible Wnt/β-catenin and Hippo-pathway experiments with G007-LK, from dose-response screening to mechanistic validation. The workflow connects APC-mutant colorectal cancer models with a reference-supported hepatocellular carcinoma use case, while emphasizing solvent control, orthogonal readouts, and troubleshooting.
Sulforaphane, PM2.5, and COPD Signaling
2026-09-01
This study links sulforaphane protection against PM2.5-induced COPD to coordinated activation of Nrf2 antioxidant signaling and suppression of EGFR/PI3K/AKT activity. Its combination of rat and cell models, network pharmacology, molecular docking, and EGFR silencing provides a mechanistic framework for studying oxidative injury and intervention response.
Thiamet G: From O-GlcNAc to Translational Strategy
2026-08-31
Thiamet G offers a controlled way to interrogate O-GlcNAc biology across tauopathy, oncology, and bone research. This thought-leadership guide connects O-GlcNAcase inhibition with Wnt-driven glycolysis and provides practical guidance for translating pathway modulation into robust experimental decisions.
PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-08-31
The reference study developed phenylboronic acid–modified PAD4 inhibitors that preferentially target tumor-associated environments while suppressing the PAD4–H3cit–NET pathway. Its lead compound reduced tumor growth and metastasis in mouse models and altered immune-cell composition, providing a preclinical framework for more selective PAD4 inhibition.
Imatinib Hydrochloride: A Phosphatase-Aware View
2026-08-30
Imatinib hydrochloride, also known as STI571 hydrochloride, is examined here through a phosphatase-aware framework for interpreting kinase inhibition. This article connects Abl, c-Kit, and PDGFR blockade with conformational control, assay design, and the limits of translating p38α mechanistic findings into cancer research.
4-Hydroxytamoxifen B6167: Workflow Guide
2026-08-29
4-Hydroxytamoxifen (B6167) is an estrogen receptor modulator for controlled DMSO-based experiments in breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte studies. It should not be selected for workflows that require aqueous or ethanol solubility, and solid-state storage is preferred over long-term storage of prepared solutions.
EGCG Nanoparticles Strengthen FLASH-RT
2026-08-29
The reference study developed functionalized, self-assembled EGCG nanoparticles, termed BENPs, to increase tumor-cell oxidative damage during FLASH-RT. In a 4T1 breast cancer model, BENPs enhanced ROS-associated DNA damage, apoptosis, tumor control, and antitumor immune activation while showing encouraging preliminary biosafety.
CFTRinh-172: A Functional Lens on CFTR Trafficking
2026-08-28
CFTRinh-172 is a selective CFTR inhibitor that helps separate channel activity from plasma-membrane abundance. This article presents a causal assay framework linking acute transport blockade with emerging CFTR trafficking research across epithelial models.
Losmapimod: p38 MAPK Mechanism and Research Use
2026-08-28
Losmapimod, also called GW856553X, is an orally active inhibitor of p38α and p38β MAPK with reported pKi values of 8.1 and 7.6. Research findings connect this target profile with inflammation signaling modulation, vascular function improvement, and investigation in hypertension and chronic obstructive pulmonary disease (COPD) models.
GCG Disrupts SARS-CoV-2 N-Protein Condensation
2026-08-27
The reference study identifies RNA-driven liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein N as a mechanism linked to viral organization and replication. It further shows that the R203K/G204R variant increases condensation-related activity, while (-)-gallocatechin gallate disrupts N–RNA condensation and suppresses viral replication, establishing a mechanistic starting point for antiviral research.
Latrunculin A: Reading Actin Perturbation
2026-08-27
Latrunculin A is a reversible inhibitor of actin assembly that can reveal how cytoskeletal state shapes cellular phenotypes and viral replication. This article translates recent actin–myosin II findings into a practical framework for designing, controlling, and interpreting perturbation assays.
Birinapant (TL32711) CRC Apoptosis Workflow
2026-08-26
Birinapant (TL32711) provides a mechanistically defined way to test IAP-dependent apoptosis resistance alongside MDM1, p53, chemoradiation, TNF, or TRAIL models. This workflow connects cIAP1/2 degradation and caspase-8 activation with practical assay controls, dosing logic, and troubleshooting guidance.
Stattic: Mechanism, Evidence, and Workflow
2026-08-26
Stattic is a small-molecule STAT3 inhibitor used to study STAT3 dimerization, transcriptional signaling, apoptosis induction in cancer cells, and radiosensitization. Product and peer-reviewed evidence support pathway-focused use in cancer biology, while the available evidence does not establish Stattic as a clinical treatment.
ROS-Responsive Nanoparticles for Cuproptosis Therapy
2026-08-25
The reference study developed ROS-responsive PHPM nanoparticles that co-deliver elesclomol and copper to intensify cuproptosis in bladder cancer models. Its combination with αPD-L1 links copper-dependent tumor killing to tumor-microenvironment remodeling and provides a mechanistic rationale for integrating nanomedicine with immune checkpoint blockade.
ECL Chemiluminescent Substrate Detection Kit Guide
2026-08-25
Learn how to use an Enhanced ECL detection kit for sensitive western blot validation of ferroptosis and PI3K/Akt/GPX4 signaling in renal cell carcinoma research. The workflow combines low-picogram protein immunodetection, extended signal stability, and practical troubleshooting for reproducible antibody detection assays.
466 records 7/32 page Previous Next First page 上5页 678910 下5页 Last page